Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center.
Acta Med Indones
October 2024
1. Department of Hematology and Medical Oncology, Dharmais National Cancer Center Hospital, Jakarta, Indonesia. 2. Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia..
Cancer is still the leading cause of death worldwide. Despite advances in diagnosis, management with the rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) chemotherapy regimen, and careful clinical and radiologic evaluation, diffuse large B-cell lymphoma (DLBCL) still carries high recurrence in clinical practice. This case series aims to assess the potential of circulating free RNA as a biomarker for evaluating therapeutic responses in DLBCL.
View Article and Find Full Text PDFDecoding the mechanisms behind second primary cancers.
J Transl Med
January 2025
Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510282, Guangdong, China.
Second Primary Cancers (SPCs) are defined as cancers that develop either simultaneously or metachronously in the same individual who has been diagnosed with and survived one primary cancer. SPCs exhibit a high incidence rate and represent the primary cause of mortality among survivors of first primary cancers. There is growing concern about the dangers of SPCs.
View Article and Find Full Text PDFIntegrating multi-omics features enables non-invasive early diagnosis and treatment response prediction of diffuse large B-cell lymphoma.
Clin Transl Med
January 2025
BOE Technology Group Co., Ltd, Beijing, China.
Background: Multi-omics features of cell-free DNA (cfDNA) can effectively improve the performance of non-invasive early diagnosis and prognosis of cancer. However, multimodal characterization of cfDNA remains technically challenging.
Methods: We developed a comprehensive multi-omics solution (COMOS) to specifically obtain an extensive fragmentomics landscape, presented by breakpoint characteristics of nucleosomes, CpG islands, DNase clusters and enhancers, besides typical methylation, copy number alteration of cfDNA.
Multiple Tolerization Subtractive Immunization in the Obtention of Specific Monoclonal Antibodies Against .
Monoclon Antib Immunodiagn Immunother
December 2024
School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Paracoccidioidomycosis (PCM) is a chronic endemic mycosis in Latin America, predominantly caused by (Pb18) and (Pl01). Diagnosing PCM is challenging due to species-specific antigenic differences, therefore new biomarkers for accurate and rapid detection are needed. This study explores multiple tolerization subtractive immunization (MTSI) to generate monoclonal antibodies against rare or weakly expressed epitopes of Pb18 and Pl01, potentially improving PCM diagnosis.
View Article and Find Full Text PDFCurrent and emerging tools for simultaneous assessment of infection and rejection risk in transplantation.
Front Immunol
December 2024
Centre for Inflammatory Diseases, Department of Medicine, Monash University, Clayton, VIC, Australia.
Article Synopsis
- Infection and rejection pose serious challenges for transplant patients, making it crucial for clinicians to effectively balance the risks associated with these complications.
- Current diagnostic strategies for assessing immune status and infection or rejection risks are imprecise, often relying on both immune and non-immune markers, complicating patient care.
- Emerging biomarkers like donor-derived cell-free DNA and urinary chemokines show promise in predicting rejection risk, potentially reducing the need for invasive biopsies and allowing for better management of immunosuppression to optimize patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!